Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-05-14

Controlled growth and production in mammalian cell culture

Obiettivo



The long term goal of this project is to design a production process for pharmaceutical proteins which includes an extended production phase in non proliferating cells. This highly innovative process will address major current industrial problems and will be based on creative application of recent developments in molecular genetics. In particular, the novel process to be created and demonstrated in this Project has clear potential to improve significantly both the quality of the pharmaceutical protein and the amount of this product obtained. This new process is based on genetic modification of CHO and BHK mammalian production cell lines so that cell proliferation can be restricted at a chosen point of the process, providing an extended interval of protein production with minimal cell growth. This should allow long-term, high- consistency product formation under technically and economically favourable conditions.
In separate but cooperating lines of research, two different types of control genes that interact in different ways with the cellular proliferation machinery will be introduced and conditionally regularly by the concentration of low-molecular-weight compounds in the medium. In one approach, expression of recombinant cyclin E, which activates proliferation in protein-free medium, will be repressed, resulting in restriction of further growth. Alternatively, proliferation inhibition will be accomplished by overexpression of an unusual tumour suppressor. Interferon Regulatory Factor 1 (IRF-l), which, unlike cyclin E, does not intervene with the cell cycle. Both of these novel proliferation control strategies will be evaluated in four specific systems: a CHO host, a BHK host, an industrial recombinant BHK cell line (B4B 1 from the Master Cell Bank of Novo Nordisk, producing Factor VII which is now in human clinical trials), and the CHO host transfected with an industrially-supplied expression vector for a pharmaceutical protein now in development for human use (s/ICAM from Thomas). The CHO and BHK hosts engineered for proliferation control will be further developed as expression systems by identifying promoters and other genetic elements which enhance productivity of growth-arrested cell. Basic studies of the physiology of all cell lines constructed in this project, including NMR studies of intracellular state, will be conducted, and suitability of these cell lines for extended, dense, stationary culture will be examined. Novo Nordisk will evaluate Factor VII production by proliferation-controlled B4Bl cells, and Thomas will produce s/ICAM using the proliferation-controlled CHO expression system constructed in this project. Both companies will characterize in detail the quality of the product, including glycosylation, made with these new systems.
The industrial significance of the concept to be developed and studied during this Project is evidenced by major commitments to the Project by two of the most important companies in Europe, Novo Nordisk and Thomas, active in protein pharmaceutical production and cell culture R&D. Although different in specifics because it is based on such recent discoveries? this project clearly embraces both the general goals and strategic approach desired for the EU Cell Factory programme.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: Il Vocabolario Scientifico Europeo.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Programma(i)

Programmi di finanziamento pluriennali che definiscono le priorità dell’UE in materia di ricerca e innovazione.

Argomento(i)

Gli inviti a presentare proposte sono suddivisi per argomenti. Un argomento definisce un’area o un tema specifico per il quale i candidati possono presentare proposte. La descrizione di un argomento comprende il suo ambito specifico e l’impatto previsto del progetto finanziato.

Invito a presentare proposte

Procedura per invitare i candidati a presentare proposte di progetti, con l’obiettivo di ricevere finanziamenti dall’UE.

Dati non disponibili

Meccanismo di finanziamento

Meccanismo di finanziamento (o «Tipo di azione») all’interno di un programma con caratteristiche comuni. Specifica: l’ambito di ciò che viene finanziato; il tasso di rimborso; i criteri di valutazione specifici per qualificarsi per il finanziamento; l’uso di forme semplificate di costi come gli importi forfettari.

CSC - Cost-sharing contracts

Coordinatore

GBF - NATIONAL CENTRE FOR BIOTECHNOLOGY
Contributo UE
Nessun dato
Indirizzo
1,Mascheroder Weg 1
38124 BRAUNSCHWEIG
Germania

Mostra sulla mappa

Costo totale

I costi totali sostenuti dall’organizzazione per partecipare al progetto, compresi i costi diretti e indiretti. Questo importo è un sottoinsieme del bilancio complessivo del progetto.

Nessun dato

Partecipanti (4)

Il mio fascicolo 0 0